FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210261317> ?p ?o ?g. }

• W4210261317 endingPage "e003539" @default.
• W4210261317 startingPage "e003539" @default.
• W4210261317 abstract "Circulating monocytes are functionally heterogeneous and can be divided into classical (CMo), intermediate (IMo), and non-CMo/patrolling monocyte (PMo) subsets. CMo can differentiate into PMo through IMo. PMos have been shown to inhibit cancer metastasis but the role of IMo is unclear. To date, no strategy has been developed to inhibit cancer metastasis through enhancing PMo/IMo differentiation.We screened multiple inflammatory cytokines/chemokines activity of modulating PMo/IMo associated cell markers expression using human monocyte in vitro culture system. We tested our candidate cytokine activity in vivo using multiple mice models. We identified critical key factors and cytokines for our candidate cytokine activity by using gene-knockout mice and neutralization antibodies.We identified IFN-γ as a candidate inflammatory cytokine in the regulation of human IMo/PMo marker expression. Our in vivo data demonstrated that IMo expansion was induced by short-term (3 days) IFN-γ treatment through increasing CMo-IMo differentiation and blocking IMo-PMo differentiation. The IMo induced by IFN-γ (IFN-IMo), but not IFN-γ activated CMo (IFN-CMo), inhibited cancer metastasis by 90%. Surprizing, the effect of IFN-γ is greater in PMo deficiency mice, indicating the effect of IFN-IMo is not mediated through further differentiation into PMo. We also found that IFN-IMos induced by short-term IFN-γ treatment robustly boosted NK cell expansion for threefold and promoted NK differentiation and function through IL-27 and CXCL9. Furthermore, we identified that FOXO1, a key molecule controlling cellular energy metabolism, mediated the effect of IFN-γ induced IL-27 expression, and that NR4A1, a key molecule controlling PMo differentiation and inhibiting cancer metastasis, inhibited the pro-NK cell and anti-metastasis activity of IFN-IMo by suppressing CXCL9 expression.We have discovered the antimetastasis and pro-NK cell activity of IFN-IMo, identified FOXO1 as a key molecule for IFN-γ driven monocyte differentiation and function, and found NR4A1 as an inhibitory molecule for IFN-IMo activity. Our study has not only shown novel mechanisms for a classical antitumor cytokine but also provided potential target for developing superior monocytic cell therapy against cancer metastasis." @default.
• W4210261317 created "2022-02-08" @default.
• W4210261317 creator A5012148881 @default.
• W4210261317 creator A5014033987 @default.
• W4210261317 creator A5016641678 @default.
• W4210261317 creator A5024712945 @default.
• W4210261317 creator A5046381538 @default.
• W4210261317 creator A5068340353 @default.
• W4210261317 date "2022-01-01" @default.
• W4210261317 modified "2023-10-12" @default.
• W4210261317 title "Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27" @default.
• W4210261317 cites W1846959033 @default.
• W4210261317 cites W1965859404 @default.
• W4210261317 cites W1966315835 @default.
• W4210261317 cites W1973112602 @default.
• W4210261317 cites W1974572279 @default.
• W4210261317 cites W1978221635 @default.
• W4210261317 cites W1978586979 @default.
• W4210261317 cites W1980409836 @default.
• W4210261317 cites W1984075660 @default.
• W4210261317 cites W1985502949 @default.
• W4210261317 cites W2009705372 @default.
• W4210261317 cites W2033068791 @default.
• W4210261317 cites W2049833483 @default.
• W4210261317 cites W2053796616 @default.
• W4210261317 cites W2063261544 @default.
• W4210261317 cites W2064505365 @default.
• W4210261317 cites W2077907997 @default.
• W4210261317 cites W2078000033 @default.
• W4210261317 cites W2092757943 @default.
• W4210261317 cites W2094278898 @default.
• W4210261317 cites W2096072078 @default.
• W4210261317 cites W2096359343 @default.
• W4210261317 cites W2099696143 @default.
• W4210261317 cites W2107482158 @default.
• W4210261317 cites W2114530568 @default.
• W4210261317 cites W2127897152 @default.
• W4210261317 cites W2130485661 @default.
• W4210261317 cites W2151362823 @default.
• W4210261317 cites W2178214143 @default.
• W4210261317 cites W2333387353 @default.
• W4210261317 cites W2336153715 @default.
• W4210261317 cites W2412261015 @default.
• W4210261317 cites W2548678995 @default.
• W4210261317 cites W2615409887 @default.
• W4210261317 cites W2731035140 @default.
• W4210261317 cites W2743567633 @default.
• W4210261317 cites W2746497061 @default.
• W4210261317 cites W2749762170 @default.
• W4210261317 cites W2757949543 @default.
• W4210261317 cites W2818021799 @default.
• W4210261317 cites W2888552632 @default.
• W4210261317 cites W2897945399 @default.
• W4210261317 cites W2914740778 @default.
• W4210261317 cites W2920141980 @default.
• W4210261317 cites W2923825520 @default.
• W4210261317 cites W2941620462 @default.
• W4210261317 cites W2991528977 @default.
• W4210261317 cites W3110807933 @default.
• W4210261317 cites W3159577409 @default.
• W4210261317 cites W31811431 @default.
• W4210261317 doi "https://doi.org/10.1136/jitc-2021-003539" @default.
• W4210261317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35091454" @default.
• W4210261317 hasPublicationYear "2022" @default.
• W4210261317 type Work @default.
• W4210261317 citedByCount "6" @default.
• W4210261317 countsByYear W42102613172022 @default.
• W4210261317 countsByYear W42102613172023 @default.
• W4210261317 crossrefType "journal-article" @default.
• W4210261317 hasAuthorship W4210261317A5012148881 @default.
• W4210261317 hasAuthorship W4210261317A5014033987 @default.
• W4210261317 hasAuthorship W4210261317A5016641678 @default.
• W4210261317 hasAuthorship W4210261317A5024712945 @default.
• W4210261317 hasAuthorship W4210261317A5046381538 @default.
• W4210261317 hasAuthorship W4210261317A5068340353 @default.
• W4210261317 hasBestOaLocation W42102613171 @default.
• W4210261317 hasConcept C121608353 @default.
• W4210261317 hasConcept C126322002 @default.
• W4210261317 hasConcept C13373296 @default.
• W4210261317 hasConcept C203014093 @default.
• W4210261317 hasConcept C2778690821 @default.
• W4210261317 hasConcept C2779013556 @default.
• W4210261317 hasConcept C2781184567 @default.
• W4210261317 hasConcept C502942594 @default.
• W4210261317 hasConcept C71924100 @default.
• W4210261317 hasConcept C8891405 @default.
• W4210261317 hasConceptScore W4210261317C121608353 @default.
• W4210261317 hasConceptScore W4210261317C126322002 @default.
• W4210261317 hasConceptScore W4210261317C13373296 @default.
• W4210261317 hasConceptScore W4210261317C203014093 @default.
• W4210261317 hasConceptScore W4210261317C2778690821 @default.
• W4210261317 hasConceptScore W4210261317C2779013556 @default.
• W4210261317 hasConceptScore W4210261317C2781184567 @default.
• W4210261317 hasConceptScore W4210261317C502942594 @default.
• W4210261317 hasConceptScore W4210261317C71924100 @default.
• W4210261317 hasConceptScore W4210261317C8891405 @default.
• W4210261317 hasFunder F4320337338 @default.
• W4210261317 hasIssue "1" @default.

• next